72F fusion protein vaccine

72F fusion protein vaccine is a candidate tuberculosis vaccine created by Statens Serum Institut (SSI). The 72F fusion protein is composed of the Rv0125 and Rv1196 proteins derived from Mycobacterium tuberculosis. Phase I clinical trials were completed in 2005 and Phase II trials are awaited.

References

Development

Classes

Administration

Vaccines

Bacterial	Anthrax Brucellosis Cholera^# Diphtheria^# Hib^# Leptospirosis Lyme disease^‡ Meningococcus^# MeNZB NmVac4-A/C/Y/W-135 Pertussis^# Plague Pneumococcal^# PCV PPSV Q fever Tetanus^# Tuberculosis BCG^# Typhoid^# Ty21a ViCPS Typhus combination: DTwP/DTaP
Viral	Adenovirus Flu^# H1N1 (Pandemrix) LAIV Hantavirus Hepatitis A^# Hepatitis B^# Hepatitis E HPV Cervarix Gardasil Japanese encephalitis^# Measles^# Mumps^# Mumpsvax Polio^# Sabin Salk Rabies^# Rotavirus^# Rubella^# Smallpox Dryvax Tick-borne encephalitis Varicella zoster chicken pox^# shingles (live) Yellow fever^# combination: MMR MMRV research: Chikungunya Cytomegalovirus Dengue Ebola Epstein–Barr virus Hepatitis C HIV
Protozoan	Malaria RTS,S research: Trypanosomiasis
Helminthiasis	research: Hookworm Schistosomiasis
Other	Androvax (androstenedione albumin) Cancer vaccines ALVAC-CEA Hepatitis B^# HPV Cervarix Gardasil NicVAX Ovandrotone albumin (Fecundin) TA-CD TA-NIC

Controversy

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.